LifeArc is a medical research charity with a 25-year legacy of helping scientists and organizations translate their research into treatments and diagnostics for patients. LifeArc turns great science into greater patient impact. The charity brings together a network of partners to tackle specific diseases and directly funds academic and early stage research. So far, LifeArc’s work has helped to develop four approved medicines (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a diagnostic test for resistance to carbapenem.
TAU BIO-LOGIC collaborated with LifeArctoproduce a humanize a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3). The collaboration has produced a lead candidate for further development and several good backup molecules offering acombination of excellent biophysical characteristics, high affinity binding, high expression and thermostability properties